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ABSTRACT 
Molecular diagnostics in tuberculosis have enabled rapid detection of Mycobacterium 
tuberculosis complex in clinical specimens, identification of mycobacteria species, 
detection of drug resistance, and typing for epidemiological investigation.  In laboratory 
diagnosis of tuberculosis, nucleic acid amplification (NAA) test is rapid, specific but not 
as sensitive as mycobacterial cultures. The primary determinant of successful NAA 
testing of tuberculosis depends on the shedding of mycobacterial DNA in secretions from 
caseating granuloma and its dissemination into sterile body fluids or tissue biopsies.  In 
multibacillary diseases with high mycobacterial load, a positive Ziehl-Neelsen (ZN) 
smear with positive NAA is diagnostic of active tuberculosis whereas a positive ZN 
smear with a negative NAA in the absence of inhibitors would indicate non-tuberculous 
mycobacterial diseases.  The role of NAA test is more important in paucibacillary 
diseases with low mycobacterial load.  But the presence of PCR inhibitors especially in 
extrapulmonary specimens may produce false negative results.  Although part of this 
inhibitor problem can be overcome by extra-extraction steps, it invariably leads to the 
loss of more mycobacterial DNA.  To circumvent this problem, a brief culture 
augmentation step before NAA to enhance the mycobacterial load with concomitant 
dilution of inhibitors can maintain the sensitivity without excessively increases in 
turnaround time.   
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INTRODUCTION  
Mycobacterium tuberculosis has infected one-third of the world’s population, and is 
currently causing 8 million new cases as well as 2 million fatalities per year (1).  In both 
developing and developed countries, a resurgence of tuberculosis including multidrug-
resistant tuberculosis (MDR-TB) has occurred among high-risk populations such as the 
human immunodeficiency virus-infected patients (1).  The control of tuberculosis mainly 
depends on rapid and accurate diagnosis, provision of effective antituberculous treatment, 
and thorough contact tracing.  Before the introduction of molecular biology into 
diagnostic mycobacteriology, direct microscopy using a Ziehl-Neelsen smear of early 
morning sputum was the only way of making a rapid diagnosis.  However, a positive 
smear requires the presence of about 104 acid-fast bacilli (AFB) per ml of sputum (2).  
Although the sensitivity could be improved by concentrating sputum sediment and 
applying auramine O fluorescent stain, direct microscopy cannot distinguish between M. 
tuberculosis and nontuberculous mycobacteria.  Therefore, a positive culture of M. 
tuberculosis remains the gold standard for diagnosis of the disease. Unfortunately, growth 
on the most affordable solid culture medium, the Lowenstein-Jensen (LJ) medium usually 
takes 4-6 weeks.  Moreover, most clinical specimens for culture, such as sputum and 
bronchoalveolar lavage require prior decontamination with N-acetyl-L-cysteine and 2% 
sodium hydroxide which invariably causes a substantial decrease in the number of 
colony-forming-units of M. tuberculosis (2).  Sensitivity is augmented by the use of an 
broth culture medium such as BacT/ALERT system, Mycobacterial Growth Indicator 
Tube (MGIT) (containing modified Middlebrook 7H9 broth), or BACTEC 460TB 
system, and their automated analogues: MGIT 960 or BACTEC 9000 MB, respectively 
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(3,4,5,6).  The mean time to detection of M. tuberculosis in smear-positive specimens 
was 13.3 days by the MGIT 960 (range 4–39) and 12.7 days by the BACTEC 9000 MB 
(range 7–21) respectively (7).  Reports of rapid diagnosis of tuberculosis by the detection 
of various mycobacterial components have not lived up to expectations.  The employed 
tools included gas chromatography-mass spectrometry assay for detection of 
tuberculostearic acid, and enzyme-linked immunosorbent assay (ELISA) for detection of 
glycolipid antigen, lipoarabinomannan antigen, and Antigen 60 of M. tuberculosis 
(8,9,10). 
 
Molecular diagnostics in tuberculosis have enabled (i) direct detection of M. tuberculosis 
complex  in clinical specimens; (ii) identification of mycobacteria, (iii) detection of drug 
resistance of M. tuberculosis, and (iv) DNA typing to address issues like reactivation of 
disease versus exogenous reinfection, and to track transmission and internal laboratory 
contamination.  These technological advancements are not intended to replace the 
conventional tests, but would rather serve as important complementary tools in the 
management of tuberculosis. 
 
 
NUCLEIC ACID AMPLIFICATION TESTS FOR RAPID DIAGNOSIS OF 
TUBERCULOSIS IN CLINICAL SPECIMENS 
In order to diagnose tuberculosis rapidly, manufacturers have developed nucleic acid 
amplification (NAA) tests specific for M. tuberculosis complex for its direct detection 
from sputum specimens. Of the two commercially available NAA tests approved by U.S. 
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Food and Drug Administration (FDA): Amplified Mycobacterium tuberculosis Direct 
Test (MTD; Gen-Probe, San Diego, California, US) and COBAS AMPLICOR M. 
tuberculosis assay (Roche Diagnostics, Mannheim, Germany), had excellent performance 
when used for testing smear-positive specimens (with sensitivity > 95% and specificity = 
100%).  The sensitivity was lower (83% to 85%) when used for testing smear-negative 
specimens, though the specificity stayed high (99%) (11). Basing on these data, the FDA 
only recommended the use of NAA tests for smear-positive respiratory specimens from 
patients who had not received antituberculous drugs for seven or more days, or within the 
last 12 months (12).  Following the initial FDA clearance, Gen-Probe enhanced the 
performance of MTD.  A large-scale study further revealed the overall sensitivity, 
specificity, positive predictive value (PPV) and negative predictive value (NPV) of the 
enhanced MTD to be 94.7%, 100%, 100%, and 98.4%, respectively for respiratory 
specimens (13).  The corresponding values were 89.4%, 100%, 100%, and 98.3%, 
respectively for smear-negative respiratory specimens.  This enhanced version of the 
MTD was eventually approved by the FDA for testing respiratory specimens, regardless 
of the smear status.  COBAS AMPLICOR M. tuberculosis assay maintains a reasonable 
sensitivity and specificity in smear positive respiratory specimens after the initial FDA 
clearance (14,15,16,17).  However, it is limited by slow block cycler amplification 
process and time-consuming colorimetric detection of the amplification products, which 
may affect the turn around time.  Recently, COBAS AMPLICOR M. tuberculosis assay 
integrates with real-time techniques using the LightCycler 2.0 instrument (Roche Applied 
Science, Penzberg, Germany). The procedure for template DNA extract remains the same 
as that of the COBAS AMPLICOR assay.  With the use of LightCycler instrument to 
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detect the amplification products, the turnaround time can be shortening.  In 146 clinical 
specimens being evaluated, good agreement (100% sensitivity, 98.6% specificity) were 
shown between the LightCycler and COBAS AMPLICOR assays (18). 
 
The early studies on NAA tests were largely laboratory-based, emphasizing  culture 
results as a major endpoint, and neglected integration of available clinical information 
into the decision making process (12).  In reality, it is mandatory to consider the degree 
of clinical suspicion for tuberculosis in determining the clinical utility of NAA tests. 
There have been a number of subsequent studies addressing the use of NAA in the 
clinical setting.  In one prospective study, the diagnostic yield of PCR in patients 
admitted to rule out pulmonary tuberculosis was studied (19).  Among 85 patients, 27 
patients had cultures positive for M. tuberculosis, 12 were smear-positive.  A positive 
PCR on at least one of two specimens collected in the first 24 hours was 85 and 74% 
sensitive, and 88 and 93% specific for tuberculosis by the in-house and Roche techniques, 
respectively.  Sensitivity in smear-negative patients was 73 and 53%, respectively.  Thus, 
PCR was found to be a useful tool to evaluate patients for tuberculosis within the first 
hospital day. In a multicenter prospective trial, a total of 338 patients with symptoms and 
signs consistent with active pulmonary tuberculosis and complete clinical diagnosis were 
stratified by the clinical investigators to be at low (≤25%), intermediate (26 – 75%), or 
high (>75%) relative risk of having tuberculosis (20).  Based on a comprehensive clinical 
diagnosis, the sensitivity of the enhanced MTD test was 83%, 75%, and 87% for low, 
intermediate, and high clinical suspicion of tuberculosis, respectively, and the 
corresponding specificity was 97%, 100%, and 100%.  PPV of the enhanced MTD test 
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was 59% (low), 100% (intermediate), and 100% (high), compared with 36%, 30% and 
94%, respectively for the AFB smear.  The investigators concluded that for complex 
diagnostic problems like tuberculosis, clinical risk assessments can provide important 
information regarding predictive values more likely to be experienced in clinical practice. 
 
Aside from the commercial NAA tests, a number of in-house studies have been 
developed over the years. On the whole, the commercial tests have comparable sensitivity 
and specificity with the in-house tests for respiratory specimens (21,22).  In addition to 
the original intention for facilitating early diagnosis of pulmonary tuberculosis, the NAA 
tests have been extensively studied in patients with extrapulmonary tuberculosis by either 
commercial kits or in-house assay (table 1) (22-50). However, the number of publications 
is too small to allow a meaningful analysis, except for a few clinical entities. For 
tuberculous meningitis, there have been quite a number of reports with test performance 
somewhat at variance (34,36,37,51).  In one study, the initial low sensitivity of 33% in 
cerebrospinal fluid could be elevated to 83% by decreasing the cutoff values for positive 
results of the MTD (34).  In a large scale study from Sweden that analyzed 154 
cerebrospinal fluid samples using the Cobas Amplicor test (Roche), the sensitivity, 
specificity, PPV and NPV were 55.6%, 97.2%, 55.6% and 97.2%, respectively (36).  In 
the most recently published systematic review and meta-analysis on the diagnostic 
accuracy of NAA tests for tuberculous meningitis (37), it has been found that the 
summary estimates in 14 studies utilizing commercial NAA tests were:  sensitivity 0.56 
and specificity 0.98.  In the 35 studies using in-house tests, the summary accuracy could 
not be established with confidence because of wide variability in test accuracy.  Thus, on 
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current evidence, commercial NAA tests show a potential role in confirming the 
diagnosis of tuberculous meningitis, although their overall low sensitivity possibly 
precludes exclusion of the disease with certainty (37).  For pleural effusion, one 
comparative study of Amplicor PCR, and conventional smear and culture methods has 
not shown a significant difference in the accuracy of diagnosis (29).  On the other hand, 
some other studies using in-house PCR have yielded rather encouraging sensitivities and 
specificities of ≥70% and ≥90%, respectively (30,31).  A recent study using real-time 
PCR assay in fine-needle aspirates and tissue biopsy specimens for diagnosing 
mycobacterial lymphadenitis revealed a sensitivity and specificity of 72% and 100%, 
respectively (27).  The former is better than conventional staining and culture techniques.  
Thus, this NAA test can provide useful support for clinical decision making in children 
with lymphadenitis. 
 
The more recently developed BDProbeTEC ET system (BD Biosciences, Sparks, Md) is 
an automated system characterized by simultaneous DNA amplification (strand 
displacement amplification) and real-time fluorometric detection.  An early evaluation of 
this direct detection system has suggested its usefulness (52, 53).  A recent study of 1131 
clinical specimens (735 respiratory specimens and 396 nonrespiratory specimens) (125 
M. tuberculosis culture-positive: 42 smear-positive), showed that the overall sensitivity, 
specificity, PPV, and NPV were respectively 90.3%, 96.9%, 78.3%, and 98.9% (54).  A 
comparative study on the performance assessment of the enhanced-MTD test and the 
BDProbeTec system has also been performed (55).  For the enhanced-MTD assay, the 
sensitivity and specificity were 88% and 99.2% respectively for respiratory specimens, 
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and 74.3% and 100% respectively for extrapulmonary specimens.  The corresponding 
values for BDProbeTec were 94.5% and 99.6% for respiratory specimens, and 92.3% and 
100% for extrapulmonary specimens, respectively.  The difference in sensitivity between 
these two systems was possibly due to better detection of inhibitors by the BDProbeTec 
system with an internal amplification control.  A recent study has further suggested the 
BDProbeTec ET System can be very useful for rapid detection of M. tuberculosis 
complex , especially in smear-negative respiratory specimens including pleural fluid (56).  
In this study, the sensitivity for smear-positive and smear-negative specimens was 100% 
and 81.5%, respectively.  While data have been limited for nonrespiratory specimens, a 
recent study revealed high sensitivity (84.7%) attained in the diagnosis of tuberculous 
meningitis (57). 
 
Data concerning the impact of the M. tuberculosis complex NAA tests on patient 
outcome have so far been gathered from uncontrolled studies or observations only, and 
are not based on well-designed clinical trials.  The impact of the NAA tests on patient 
outcome mainly depends on the status of the AFB smear.  In smear-positive patients, 
hospital infection control and public health resources are largely affected, regarding drug 
therapy and isolation of hospitalized patients for air-borne infections, as well as contact 
investigations.  Appropriate use of isolation beds is especially important in high 
prevalence areas, regional outbreaks, or where such beds are scarce.  In smear-negative 
patients, the NAA test has a greater potential in influencing the outcome of patients 
regarding treatment, and avoiding the need for costly and/or risky diagnostic 
investigations/procedures.  Thus, molecular diagnostics of M. tuberculosis complex  has a 
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potential to improve clinical care through a substantial reduction in the time required for 
mycobacterial detection, and may provide material savings in the overall cost of care of a 
patient.  A cost-effectiveness analysis of the MTD (Gen-probe) direct test as used 
routinely on smear-positive respiratory specimens has been published recently (58).  The 
authors considered that while routine MTD testing of smear-positive specimens would 
not be expected to have cost saving for most individual hospitals, centralized reference 
laboratories might be able to implement MTD in a cost-effective manner across a wide 
range of settings.  Prospective studies are required concerning the cost-effectiveness of 
NAA tests in patients suspected to have tuberculosis.  While awaiting more clues for 
evidence-based practice, one pragmatic approach at present is still to concentrate using 
NAA tests for smear-positive patients with intermediate or low probability of 
tuberculosis, and smear-negative patients with high or intermediate clinical suspicion of 
the disease. 
 
Although the NAA tests provide a rapid diagnosis for pulmonary and extrapulmonary 
tuberculosis, the sensitivity is still far from ideal. The limitation of the utility of NAA 
tests is largely attributed to the lack of shedding from patients with tuberculosis and the 
susceptibility of the amplification reaction to the inhibitor.  Secretion of antigens from the 
bacterial cell of M. tuberculosis invariably excites a granulomatous inflammation in 
immunocompetent hosts which produces a walling off effect by the epithelioid cells and 
fibroblast at the site of infection.  No bacteria will be shed and excreted via the luminal 
passages such as the airway into the exterior or potential body cavities such as 
peritoneum, pericardium, pleura, synovium, and arachnoids.  Shedding only starts to 
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occur when the granulomatous inflammation is so severe that caseous necrosis has 
occurred with erosion into the mucosal lumen or coelomic cavity.  In the case of the 
airway, the necrotic material carrying the AFB is carried by the mucociliary blanket and 
coughed into the environment. It is usually at this stage that a diagnosis can be made in 
an immunocompetent host using either culture or NAA test.  It is also important to note 
that extrapulmonary specimens such as whole blood and various body fluids could be 
more useful clinical specimens in immunosuppressed hosts where mycobacterial 
dissemination readily occurs without the walling off effect of granulomatous 
inflammation.  As expected, studies have shown a reasonable sensitivity of NAA test 
using peripheral blood in AIDS patients with tuberculosis (45).   
 
Although the advantage of NAA over culture is that the sensitivity is not decreased by the 
prior decontamination step, this advantage is offset by inhibitors of the polymerase 
enzyme.  The incidence of such inhibitors varies from 4% in pulmonary to 18.6% in 
extrapulmonary specimens (59).  Part of this inhibitor problem can be overcome by 
refining the nucleic acid extraction step.  But these extra-extraction steps invariably lead 
to the loss of more mycobacterial DNA.  This is a serious problem in extrapulmonary 
tissue specimens where inhibitors are especially abundant (59).  This may be 
circumvented by a short culture augmentation step with concomitant dilution of 
inhibitors. A brief culture of 2 to 3 days on LJ medium significantly increased the 
sensitivity of NAA tests in tissue samples exerting PCR inhibition from 63% to 92% 
(60). False positive results from NAA tests could be minimized by automated testing, 
good laboratory practice, and the use of uracil-N-glycosylase (UNG) and dUTP-UNG 
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(2,61).  However, biological false positive has also been reported as a result of the 
shedding of dead mycobacteria after adequate antituberculous treatment (62).  Except for 
the turnaround time, the initial expectations that these NAA tests are at least as rapid as 
the ZN smear, more sensitive and specific than the smear, more sensitive than the culture, 
especially those smear negative specimen from extrapulmonary sites where the diagnosis 
is always difficult due to the paucibacillary nature of the disease, have not been fulfilled 
(63).   
 
 
RAPID IDENTIFICATION OF MYCOBACTERIA BY MOLECULAR 
TECHNIQUES 
Identification of mycobacteria by growth characteristics and conventional biochemical 
tests takes many weeks.  The CDC has recommended use of more rapid identification 
methods, such as nucleic acid probes, the NAP (p-nitro-α-acetylamino-β-
hydroxypropiophenone) test, and high-performance liquid chromatography (64). 
 
Several systems exist for the rapid identification of mycobacterial species from cultured 
isolates (64).  The MicroSeq 500 system (Applied Biosystems, Foster City, California, 
US) is an assay based on sequencing a portion of the 16S rDNA gene (65,66,67).  It is 
time-consuming to perform and requires sophisticated instrumentation for data analysis.  
The AccuProbe assay (Gen-Probe, San Diego, California, US), a chemiluminescent DNA 
probe, involving hybridization with species-specific probes, is highly specific.  But the 
test is only able to identify a limited number of species (68).  Like MicroSeq 500 system, 
it cannot differentiate M. tuberculosis from the other species in the complex.  DNA strip 
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assays based on the reverse hybridization of PCR products to oligonucleotide probes 
bound on a membrane strip can be applied to identify myccobacterial species.  Two 
commercial preparations of DNA strip assay are available for laboratory diagnosis (68).  
Inno-LiPA Mycobacteria (Innogenetics NV, Ghent, Belgium) identifies mycobacteria by 
the 16 to 23S rDNA spacer region of Mycobacterium species (69) and GenoType 
Mycobacteria (Hain Lifescience, Nehren, Germany) identifies mycobacteria by 23S 
rDNA of Mycobacterium species (70).  Both can also identify M. tuberculosis from 
clinical isolates (70,71) or broth culture systems (72), but does not allow differentiation 
among members of the M. tuberculosis complex.  A single test can identify a range of 
species (73).  Inno-LiPA assay has been recently improved (Inno-LiPA Mycobacteria v2) 
by increasing the number of identifiable mycobacterial species to 16 (74). GenoType 
assay can identify 13 clinically important mycobacterial species.  In a prospective 
evaluation of 178 clinical isolates, GenoType assay produced an overall agreement of 
89.3% with AccuProbe assay and 16s rDNA sequencing (70).  Other rapid identification 
method included PCR amplification-restriction analysis of the rpoB DNA which can 
detect pathogenic mycobacteria including M. tuberculosis complex in clinical specimens 
(75). 
 
Furthermore, an extension of the principle of solid phase detection of nucleic acids has 
been developed.  Using high-density DNA probe arrays on a microchip, the system can 
provide rapid strain identification, as well as, assessment of drug resistance in cultured 
isolates (76,77).  While these microarrays are technologically advanced, the associated 
cost can be great.  One simpler way is to use the peptide nucleic acids probes as an in situ 
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hybridization assay by a fluorescent stain format.  Peptide nucleic acids are DNA-like 
structures in which the sugar-phosphate backbones are replaced with peptide-like 
structures.  The binding of peptide nucleic acid to DNA is sequence specific, and the 
interaction is stronger than that of a DNA-DNA interaction.  This technology has been 
found to work well for cultured isolates, and formalin-fixed histological samples (78,79). 
 
RAPID DRUG SUSCEPTIBILITY TESTING USING MOLECULAR 
TECHNIQUES 
Giving an effective antituberculous drug combination is as important as making a rapid 
and accurate diagnosis of tuberculosis.  Without a rapid drug-susceptibillity testing 
method, most clinicians are prescribing a standard regimen empirically for patients with 
no known risk factors for drug-resistant disease.  Traditionally, drug-resistance testing 
requires the growth of sufficient bacterial colonies in order to allow standardization of 
inoculums used in the agar proportion method (2), which usually takes another 2 weeks.  
The turnaround time is shortened to only 4 days with the BACTEC 460TB methods, 
which incorporates standard dilution of antituberculous drugs (isoniazid, rifampicin, 
pyrazinamide, ethambutol, and streptomycin) in the broth medium and monitor the 
growth curve after inoculation (2).   
 
With unraveling of the genetic basis of antituberculous drug resistance through 
identification of the main genes in question (80), namely rpoB (rifampicin), katG 
(isoniazid), inhA (isoniazid and ethionamide), ahpC (isoniazid), pncA (pyrazinamide), 
embB (ethambutol), rrs (streptomycin), and rpsL (streptomycin) and gyrA 
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(fluoroquinolone), various molecular techniques for detection of drug resistance (largely 
against rifampicin, isoniazid, pyrazinamide and streptomycin) in M. tuberculosis have 
been evaluated.  These principally include direct DNA sequencing (81), heteroduplex 
(82), and restriction fragment length polymorphism (83), as well as oligonucleotide 
arrays (84).  Two commercial forms of the molecular assays, namely INNO-LiPA Rif.TB 
(Innogenetics, Belgium) and MisMatch Detect II (Ambion, U.S.A.) have performed well 
by correlating with standard methods of detection of M. tuberculosis and rifampin 
susceptibility testing in 94.7% and 100% smear-positive respiratory specimens, 
respectively (85).  For the cultured isolates, the correlations reached 100%.  The former 
technique is a line probe assay based on the reverse hybridization principle.  The latter 
represents a RNA/RNA duplex, base pair-mismatch assay.  Direct DNA sequencing and 
DNA arrays also appear very promising for future use due to high sensitivity and 
specificity.  In recent years, there have been additional reports on direct detection of 
rifampicin and isoniazid resistance rapidly in M. tuberculosis strains present in clinical 
specimens.  Most of the techniques embrace the use of improved PCR amplification, such 
as real-time PCR (86) or allele-specific on-chip PCR (87).  Another new development in 
recent years has involved the molecular beacons.  These are molecules that emit light 
following upon a chemical reaction involving a colored fluorophore (88).  Such 
molecular beacon assays based on binding of DNA primers with specific targets in PCR 
amplicons can provide a rapid and sensitive method of diagnosing drug resistance (89).  
However, application of DNA arrays and molecular beacons is associated with high cost.  
A recent study has described the potential utility of the peptide nucleic acid probes in 
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detecting mutated KatG and rpoB genes in M. tuberculosis (90).  This study utilizes the 
PCR-ELISA format and is likely to be more economical. 
 
UTILITY OF MOLECUAR FINGERPRINTING IN TUBERCULOSIS 
Tuberculosis often has a long incubation period which makes outbreak investigations 
more difficult than for other acute respiratory infections. Discriminatory typing methods 
would have an important place in the confirmation of clusters in outbreak investigations 
especially in areas where the disease is highly endemic. Strain typing has been used in 
community or institutional outbreaks involving family households, prisons, laboratory 
cross-contamination and outbreaks due to drug-resistant strains (91,92,93). These typing 
techniques are also important in the differentiation of reactivation or exogenous 
reinfection. At the national level such tests could also be used for the evaluation of 
regional control programs and will allow the design of more rational control measures. In 
the last 10 years, the most widely used technique is restriction fragment length 
polymorphism (RFLP) analysis of chromosomal DNA using IS6110, an insertion 
sequence found throughout the M. tuberculosis complex, typically in 5 to 20 copies (94).  
While general principles regarding interpretation of RFLP patterns are present, there are 
no universally accepted criteria.  Besides, the analysis is labor-intensive and cannot be 
applied to strains with five or fewer copies of IS6110, which are not uncommon in some 
communities rendering this approach less useful (95).  Other fingerprinting techniques 
that have been developed to complement RFLP analysis include blotting for polymorphic 
guanine-cytosine-rich sequences (96), substituting IS1081 (97) or other repeat sequences 
such as the variable-number tandem repeats (98), and spoligotyping (99).   
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 OTHER POTENTIAL UTILITY OF MOLECULAR DIAGNOSTICS IN 
TUBERCULOSIS 
Molecular detection of mycobacterial DNA has also been investigated regarding its 
potential to predict treatment success, failure or relapse. Initially monthly qualitative PCR 
on sputum specimens were performed. The majority of the treated patients either did not 
produce sputum or have a negative PCR test by 6 months (62). Around 30% had 
persistent positive test but most of these patients had extensive pulmonary disease, 
underlying medical problems (62). A small number of these persisters actually had 
known MDR-TB which accounted for the failure (62). Most of these persisters could be 
explained by the persistent shedding of dead AFB. Since microbial load is the result of 
the dynamic interaction between the microbe, the host defense and the drug treatment, a 
serial quantitative monitoring of the microbial load throughout the course of treatment 
may be important for both prognostic predictions and individualization of the regimen 
and duration in the long run. This is possible with the advent of the real time PCR using 
the LightCycler (100). However studies comparing the quantitation by AFB smear, 
colony counts and genome copies by quantitative PCR showed that the initial bacillary 
load are only well correlated before treatment. But the rate of disappearance of the AFB 
and the quantity of DNA did not correlate with the rate of decline of the viable colony 
count and therefore not useful for monitoring of the efficacy of drug treatment. This was 
not unexpected since positive smears are well known to persist for years in patients with 
severe cavitary disease leading to extensive lung destruction. The hard cell wall of 
mycobacteria may well have protected the microbial DNA from host enzymatic 
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degradation. There were attempts to use relatively shorter lived mRNA encoding 85kDa 
protein for monitoring the progress (101).  The clinical usefulness of such approach 
would await validation by quantitative PCR in larger clinical studies. 
 
MOLECULAR DIAGNOSTICS FOR HOST SUSCEPTIBILITY 
The future of the molecular diagnostic test for tuberculosis will no longer be confined to 
the bacterial genome. The unfolding of the human genome has led to the discovery of 
more susceptibility or resistance genes associated with tuberculosis (102). These genes 
are related to effective killing of intracellular mycobacteria or granuloma formation. The 
effector mechanisms include the iron scavenging function of transport proteins of 
macrophages which competes with the siderophores of mycobacterium, the activation of 
macrophage function by Vitamin D, the antigen presentation, and even the cytokines, 
cytokine receptors and intracellular signaling molecules which are part of the 
immunological pathway of activation for a T-cell helper-1 response (103). Important 
examples are the natural resistance associated macrophage protein (NRAMP-1), Vitamin 
D receptor, HLA-DR2 and HLA-DQB1 loci, on chromosome 15 and X (104,105,106).  
Importance of the mutations involving the receptors IFN R1, IFN R2, STAT1, IL12R β1 
associated with interferon-γ mediated immunity is uncertain in tuberculosis though they 
have been found to be linked to disseminated diseases due to atypical mycobacteriosis 
and other intracellular pathogens (107,108). The use of microarray for a host genome 
survey of tuberculosis susceptibility would not be too far from reality.  
 
CONCLUSION 
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In the past decade, there has been an exuberant progress in the discovery and evaluation 
of new techniques in molecular diagnosis for tuberculosis.  Many of these are likely to 
have major complementary roles to the conventional tests.  Some technologies have 
opened up potentially novel approaches in the fight against this important infectious 
disease worldwide.  As for new drugs, the use of these new diagnostics is also fraught 
with budgetary considerations.  This is especially relevant in the developing world with 
heavy disease burdens and severely compromised resources.  Thus, continuing efforts 
must be made to address the clinical applicability and cost-effectiveness of these novel 
tools in the strategic management of tuberculosis globally. 
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Table 1.  Overview of sensitivity and specificity of polymerase chain reaction using 
either in-house or commercial methods in detection of Mycobacterium tuberculosis from 
direct clinical specimens 
 Overall sensitivity 
(%)! 
 
Overall specificity 
(%) 
Ref 
Anatomical site    
Pulmonary     
Respiratory specimens*  77.1 - 100  99.3 - 100 22,23 
Gastric aspirates 44 - 60  93.7 - 98 24 
PTNA@ 65 100 25 
    
Extrapulmonary    
Lymph node  
(fresh tissue) 
71.6 - 87.5 NM 26,27$ 
Pleural fluid 27.3 - 81 90 - 100 28-32 
Pleural biopsy 90 100 33 
Cerebrospinal fluid 31.4 - 56 98  34 - 37 
CAPD fluid  CR CR  
Ascite fluid  CR CR  
Liver biopsy tissue  
(paraffin-embedded)  
58 - 88 96 - 100 38, 39 
Urine  55.6 - 95.6 98.1 - 98.9 40, 41 
Skin  60 - 80 100 42, 43 
Bone & synovial tissue CR CR  
Peripheral blood  30.4 - 100 #  NM 44 - 46 
Marrow blood 42 - 73.2 NM 47, 48 
Paraffin-embedded tissues 
 
60 - 68 NM 49, 50 
Note.  ! Mycobacterium tuberculosis culture as gold standard for respiratory specimens whereas clinical 
diagnosis with or without radiological and histological findings as gold standard for other specimens;  * 
sputum, bronchoalveolar lavage fluid, endotracheal aspirates; @ Percutaneous transthoracic needle 
aspiration # 82% in HIV-positive; $ Real-time PCR is performed; CR, case report only; NM, not mentioned; 
PCR, polymerase chain reaction; Ref, references 
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